These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7353371)

  • 21. [Pathological analysis of renal osteodystrophy in 194 cases].
    Yu YF
    Zhonghua Bing Li Xue Za Zhi; 1991 Dec; 20(4):280-3. PubMed ID: 1813163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 23. Ultrastructural aspects of bone mineralization in renal osteodystrophy.
    Bonucci E
    Adv Exp Med Biol; 1977; 81():477-91. PubMed ID: 409106
    [No Abstract]   [Full Text] [Related]  

  • 24. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrastructural development of hyperosteoidosis in 1,25(OH)2D3-treated rats fed high levels of dietary calcium.
    Boyce RW; Weisbrode SE; Kindig O
    Bone; 1985; 6(3):165-72. PubMed ID: 3839678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
    Reutter FW; Sieber R; Olah AJ; Dambacher MA
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy.
    Aoki C; Uto K; Honda K; Kato Y; Oda H
    Lab Invest; 2013 Nov; 93(11):1170-83. PubMed ID: 23979426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcitriol in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
    Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term administration of vitamin D steroles in incipient and advanced renal failure: effect on bone histology.
    Malluche HH; Ritz E; Werner E; Meyer-Sabellek WA
    Clin Nephrol; 1978 Dec; 10(6):219-28. PubMed ID: 215365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in vitamin D metabolism as they pertain to chronic renal disease.
    Coburn JW; Hartenbower DL; Brickman AS
    Am J Clin Nutr; 1976 Nov; 29(11):1283-99. PubMed ID: 187055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1,25-dihydroxycholesterol treatment of long-term haemodialysed patients with renal osteodystrophy.
    Váry L
    Int Urol Nephrol; 1980; 12(3):241-7. PubMed ID: 7251289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats.
    Jablonski G; Mortensen BM; Klem KH; Mosekilde L; Danielsen CC; Gordeladze JO
    Calcif Tissue Int; 1995 Nov; 57(5):385-91. PubMed ID: 8564802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 24,25 dihydroxycalciferol: assay in non-anephric patients on chronic haemodialysis and assessment of its possible pathophysiological role in renal osteodystrophy.
    Lambrey G; Nguyen TM; Fournier A; Sebert JL; Kassouf J; de Fremont JF; Marie P; Meunier P; Caillens C; Gueris J; Garabedian M; Balsan S
    Proc Eur Dial Transplant Assoc; 1980; 17():548-56. PubMed ID: 6972530
    [No Abstract]   [Full Text] [Related]  

  • 36. A versatile new mineralized bone stain for simultaneous assessment of tetracycline and osteoid seams.
    Villanueva AR; Lundin KD
    Stain Technol; 1989 May; 64(3):129-38. PubMed ID: 2480003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does uremic bone disease warrant early treatment with calcitriol?
    Chesney RW
    Arch Intern Med; 1980 Aug; 140(8):1016-7. PubMed ID: 6893117
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical use of synthetic 1,25-dihydroxycholecalciferol.
    Evans IM; Boulton-Jones M; Doyle FH; Joplin GF; Lockwood M; Matthews EW; MacIntyre I
    Calcif Tissue Res; 1976 Aug; 21 Suppl():236-41. PubMed ID: 782663
    [No Abstract]   [Full Text] [Related]  

  • 39. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW; Brickman AS
    Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
    [No Abstract]   [Full Text] [Related]  

  • 40. Appearance of electron-dense segments: indication of possible conformational changes of pre-mineralizing collagen fibrils in the osteoid of rat bones.
    Asawa Y; Aoki K; Ohya K; Ohshima H; Takano Y
    J Electron Microsc (Tokyo); 2004; 53(4):423-33. PubMed ID: 15582942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.